Engflag

Nizonide - O

Quick links to important sections

Nizonide - O

Nizonide - O_EN

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nizonide - O

Property Description
Active Ingredients Nitazoxanide, Ofloxacin
Form Oral Tablet
Pharmacological Class Broad-spectrum Anti-infective Agents
Common Use Addresses complex or mixed parasitic and bacterial infections
Origin Synthetic

What Type of Medicine is Nizonide-O?

Nizonide-O is defined as a synthetic, Fixed-Dose Combination Product that functions as a broad-spectrum anti-infective agent. This preparation is specifically formulated as an oral tablet for administration. As a Fixed-Dose Combination Product, Nizonide-O strategically combines two distinct active pharmaceutical ingredients within a single medication unit, ensuring simultaneous delivery of the therapeutic agents. The overall preparation is categorized under the high-level class of Anti-infective Agents, a group clinically recognized for its essential role in combating the growth of pathogenic organisms.

The Composition: Nitazoxanide and Ofloxacin

The composition of Nizonide-O includes the active ingredients Nitazoxanide and Ofloxacin, both of which are fully synthetic compounds. Nitazoxanide is pharmacologically classified as a unique thiazolide antiprotozoal drug, acting primarily via its active metabolite, Tizoxanide. The second component, Ofloxacin, is defined as a Fluoroquinolone Antibiotic. This pairing ensures the tablet delivers agents from two different pharmacological classes, establishing its unique differentiation as a dual-target medicine. The preparation utilizes the distinct mechanisms of action of these two components.

General Therapeutic Purpose: Dual-Action Approach

The general therapeutic purpose of Nizonide-O is to achieve a comprehensive anti-infective outcome through its dual-action approach. The combination is strategically designed to provide a synergistic effect, which refers to the principle where the combined activity of the two agents is greater than their individual effects alone. This dual approach enhances the medication’s capability to comprehensively target and neutralize a wider spectrum of disease-causing organisms. This medicine is typically reserved for addressing complex infections that involve both susceptible bacterial and protozoal pathogens, a frequent scenario in gastrointestinal complaints.

Regulatory References

  1. Anti-infective Agents
  2. Ofloxacin drug profile

What side effects are possible with Nizonide - O?

Possible side effects and safety information

The official safety profile for the fixed-dose combination of Nitazoxanide and Ofloxacin is structured around the documented adverse reactions and specific regulatory warnings associated with its two components. This information is classified by frequency and the body system affected, strictly according to government regulatory documents.

Documented Adverse Reactions and Frequency

Adverse reactions classified as Common (occurring in 2% of patients in component trials) primarily involve Gastrointestinal disorders and Nervous System disorders. These may include abdominal pain, nausea, headache, and dizziness. An additional common, non-serious effect associated with Nitazoxanide is Chromaturia (discolored urine).

Serious Safety Considerations

The most serious regulatory warnings are linked to the Ofloxacin component, a fluoroquinolone antibiotic. These warnings highlight the risk of disabling and potentially irreversible adverse reactions affecting the musculoskeletal and nervous systems. Serious reactions include Tendon Rupture and Peripheral Neuropathy (nerve damage)

, which may occur during treatment or up to several months after cessation. Additional serious safety concerns include severe Central Nervous System effects (e.g., seizures, confusion, psychiatric disturbances) and the potential for QT interval prolongation.

Population-Specific Safety Notes

The official labeling notes specific safety considerations for certain populations. There is a documented increased risk of tendon rupture in older adults. Furthermore, the medicine should be used with caution in patients with pre-existing renal or hepatic impairment due to unstudied pharmacokinetics in these groups. The medicine is officially contraindicated in patients with prior hypersensitivity to either Nitazoxanide or agents of the quinolone class. Some neurological effects may be observed following the first dose of the medicine.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Nizonide - O

Overdose Scope

Documented overdose presentations:

  • Symptoms documented for the Ofloxacin component (Fluoroquinolone class) may include drowsiness, nausea, dizziness, and confusion.
  • Other reported signs can involve slurred speech, numbness, and swelling of the face.
  • Regulatory information for the Nitazoxanide component is limited; high single doses up to 4000 mg have been officially administered without specific adverse effects documented in healthy adults.

Physiological systems affected (as stated in label):

  • The official warnings cite severe effects on the Central Nervous System (CNS), Peripheral Nerves (e.g., peripheral neuropathy), and the Cardiovascular System (e.g., risk of QT interval prolongation).

Dose-related or exposure-related factors (if applicable):

  • The official label notes an increased risk of tendon problems for patients who are over 60 years of age or those with severe kidney problems.

Emergency-response statements (as written in official documents):

  • Patients should be observed and given symptomatic and supportive treatment.
  • Gastric lavage may be officially appropriate soon after oral administration (Nitazoxanide component).

When immediate medical help is required (label-derived phrasing only):

  • Seek immediate medical attention if an overdose is suspected.
  • Urgent help is mandated if the patient exhibits collapse, experienced a seizure, has trouble breathing, or cannot be awakened.

Overdose Classifications (High-Level)

Severity classification (as defined in official documents):

  • The Ofloxacin component is associated with official warnings regarding disabling and potentially permanent serious effects and life-threatening outcomes, including tendon rupture.

Regulatory basis (EMA / FDA / etc.):

  • FDA Prescribing Information and Fluoroquinolone Class Safety Communications.

Overdose-context constraints (as defined in official documents):

  • No specific antidote is known for overdose with the Nitazoxanide component.

Resulting Overdose Structure

Official overdose statements:

  • The regulatory documentation mandates immediate medical attention for suspected overdose or if severe neurological or respiratory compromise occurs.
  • Management involves symptomatic and supportive treatment, including the potential for gastric lavage.
  • The profile highlights the severe risks of seizures and tendon complications that are documented in the Ofloxacin component’s class warnings.

Connection to the overall overdose profile (2–4 sentences): Government regulatory documents define this overdose profile by documenting expected initial presentations like dizziness and confusion, while emphasizing that severe signs require immediate medical attention. Official management focuses on observation and supportive treatment due to the absence of a specific antidote, and special warnings are provided regarding complications like tendon problems in specific populations, as documented in the label.

Therapeutic Uses of Nizonide - O

Nizonide-O is a combination medication containing Nitazoxanide and Ofloxacin for the management of certain infections. It is generally designated for use in adult and pediatric patients to address a range of issues caused by susceptible organisms, including specific types of protozoa (parasites) and bacteria.

Quick Facts

  • Primary Indications: Addresses diarrhea associated with certain protozoal and bacterial infections.
  • Protozoal Targets: Utilized for infections caused by Giardia lamblia and Cryptosporidium parvum in immunocompetent individuals.
  • Bacterial Action: Contains an ingredient that assists in inhibiting the growth of susceptible bacteria.

This treatment option is used for the treatment of diarrhea caused by Giardia lamblia or Cryptosporidium parvum in specific patient populations. The second component of the medication is also designated to address susceptible bacterial organisms that may contribute to gastrointestinal infection. The application of this medication is based on the characteristics of the infection and the patient's immune status, particularly regarding those who are immunocompromised. The medicine's function is to help manage the overall course of the infection.

Eligibility and Restrictions for Use

Who Can and Cannot Use Nizonide - O?

Eligibility to use Nizonide-O, a combination of Nitazoxanide and Ofloxacin, is determined by official regulatory rules governing its two components. Use is strictly limited to certain populations.

Absolute Non-Eligibility (Contraindications)

  • Hypersensitivity: Individuals with a known allergy to Nitazoxanide, Ofloxacin, or any other Quinolone antibiotic must not use this medicine.
  • Tendon and Muscle Conditions: Patients with a history of tendinitis or tendon rupture related to fluoroquinolone use, or those with Myasthenia Gravis, are contraindicated.

Population and Organ Function Restrictions

Population Group Regulatory Status
Pediatric (Under 12) Not Recommended for the tablet form; the dose exceeds the amount suitable for this age group.
Pregnant/Breastfeeding Not Recommended due to insufficient human data and potential risk from the Ofloxacin component.
Renal/Hepatic Impairment Use with Caution is required, as the pharmacokinetics in these specific patient groups have not been established.
Immunocompromised Efficacy is Not Established for the treatment of certain protozoal infections in HIV-infected or immunodeficient patients.

Older adults may use the medicine but require caution due to an increased risk of tendon rupture associated with the Ofloxacin component.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Nizonide-O primarily based on its two active components, Nitazoxanide and Ofloxacin. This profile includes specific restrictions, mandatory timing rules, and exposure modifications.

Contraindicated Combinations and Pharmacodynamic Risks

Co-administration with other medicinal products known to prolong the QTc interval is formally classified as a contraindicated combination. This pharmacodynamic restriction applies to agents such as certain Class IA and III Antiarrhythmics, Tricyclic Antidepressants, and Macrolides, due to the potential for an additive effect from the Ofloxacin component.

Additionally, co-administration with corticosteroids is associated with an enhanced risk of tendinopathy and tendon rupture.

Pharmacokinetic and Absorption Constraints

The Ofloxacin component's absorption is subject to chelation-based pharmacokinetic interference. Substances containing multivalent cations—such as Antacids, Sucralfate, or Iron/Zinc supplements—cause a significant reduction in Ofloxacin absorption.

To mitigate this, the mandatory regulatory requirement is that these multivalent cation-containing products must be administered at least 2 hours before or 2 hours after the medicine. The Nitazoxanide component is documented to require administration with food, as food significantly increases the systemic exposure (AUC and Cmax) of its active metabolite, tizoxanide.

Exposure Modification

The Ofloxacin component is reported to increase the effect of co-administered oral anticoagulants (e.g., Warfarin).

Mechanism of Action

How Nizonide - O Works

The mechanism of this combination drug involves two distinct, simultaneous, and lethal attacks against susceptible pathogens, targeting their fundamental requirements for life.

1. Sabotage of Anaerobic Pathogen Energy (Nitazoxanide)

This mechanism focuses on inhibiting the Pyruvate:ferredoxin oxidoreductase (PFOR) enzyme, which is critical for the energy metabolism of susceptible protozoa and strict anaerobic bacteria. By blocking the electron transfer essential for this pathway, the drug causes severe ATP depletion and energy starvation within the pathogen, leading directly to the loss of cellular viability.

2. Destruction of Bacterial Genetic Integrity (Ofloxacin)

The second mechanism targets the core genetic machinery of bacteria, specifically inhibiting DNA Gyrase and Topoisomerase IV. These enzymes are vital for managing DNA structure during replication and cell division. Ofloxacin stabilizes the cleaved-DNA-enzyme complexes, preventing the repair of the strands and causing an accumulation of lethal DNA breaks, which initiates a rapid bactericidal (killing) effect against a broad spectrum of susceptible bacteria.

3. Dual-Target Pathogen Mechanism

The combination mechanism provides dual targeting by utilizing two distinct, unlinked lethal mechanisms. One component starves anaerobic pathogens, while the other destroys the genetic material of aerobic and susceptible anaerobic bacteria. This approach ensures two distinct lethal mechanisms are deployed simultaneously.

Dosage and Administration Information

Administration and Dosing of Nizonide - O

Nizonide - O is a fixed-dose oral tablet combining nitazoxanide and ofloxacin. Adherence to the prescribed regimen is essential to maintain steady therapeutic concentrations of both components and ensure completion of the course.

Official Dosing and Administration

Administration Parameter Guideline
Route of Administration Oral (by mouth)
Standard Dosing Schedule One tablet every 12 hours
Duration of Treatment 3 days (must complete the full course)
Timing in Relation to Meals Must be taken with food
Preparation Swallow the tablet whole. Do not crush, chew, or break
Age-Group Rule Use of the tablet is recommended for patients 12 years of age and older. Use is not recommended for pediatric patients 11 years of age or younger

Handling Missed Doses

If a dose is missed, take the dose as soon as the omission is recognized. However, if it is almost time for the next scheduled dose, the missed dose should be skipped, and the patient should return to the regular dosing schedule. Do not take two doses at the same time to make up for a missed dose.

These instructions define the procedural steps for using Nizonide - O, mandating a specific, short-term, twice-daily regimen that requires co-administration with food to optimize drug absorption and maintain the required concentration profile.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Nizonide-O

Evidence Base for Giardia lamblia Infection (Giardiasis)

Research related to Giardia lamblia infection primarily utilized Randomized Controlled Trials (RCTs) designed to evaluate the Nitazoxanide component against placebo or other agents. Researchers focused on assessing the time measured until symptomatic status change related to acute diarrhea and the absence of the parasite in stool samples. These findings describe group patterns, not personal outcomes, and reflect the specific conditions under which the studies were conducted.

The evidence base for the Nitazoxanide component in immunocompetent patients has been reviewed as substantial in regulatory records. However, the available research provides limited insight into long-term outcomes, as follow-up durations were typically short-term, and there are few data available for the specific Fixed-Dose Combination (FDC) product, Nizonide-O, in major official summaries compared to the individual components.

Evidence Base for Cryptosporidium parvum Infection (Cryptosporidiosis)

The clinical evaluation for infections caused by Cryptosporidium parvum relied mainly on Randomized, Double-blind, Placebo-Controlled Trials. Research monitored outcomes related to systemic or functional imbalance, such as the time measured until symptomatic status change of acute watery diarrhea and whether parasite oocysts were absent in the stool. These studies focused on immunocompetent adults and children.

A critical limitation noted in official research summaries is the lack of evidence supporting the use of this treatment in immunocompromised patients. Data for this specific group remain insufficient. As with giardiasis, the research evidence for the Nizonide-O FDC product is not the primary basis of the regulatory research summaries, and long-term effects are not fully established.

Studies in Specific Patient Groups (Special Populations)

Research has evaluated the Nitazoxanide component in pediatric patients (children ages 1 to 11 years) for both Giardia lamblia and Cryptosporidium parvum infections. The studies were designed to measure clinical and parasitological status. Findings described patterns observed in these pediatric populations, consistent with the data collected in adult studies.

However, studies exploring the use of the treatment in immunocompromised individuals have limited information. The current research results apply only to the immunocompetent populations studied, and data for certain groups remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Nizonide - O (FAQ)

Q: What is Nizonide - O used to treat?

Nizonide - O is officially indicated for the treatment of diarrhea caused by specific protozoan parasites, primarily Giardia lamblia and Cryptosporidium parvum. According to regulatory documents, the medicine acts by interfering with the energy metabolism of these parasites, which is believed to help in treating the infection.

Q: Can Nizonide - O be used for stomach flu (viral gastroenteritis)?

Official product information states that Nizonide - O is an antiparasitic agent, specifically approved to treat diarrhea caused by certain protozoa, such as Giardia and Cryptosporidium. It is not indicated for treating viral infections like the stomach flu (viral gastroenteritis), as its mechanism targets parasites.

Q: Is Nizonide - O an antibiotic?

No, Nizonide - O is classified as an antiparasitic agent, rather than a traditional antibiotic. Regulatory documents define it as a nitrothiazole derivative, which works by targeting protozoan parasites responsible for certain diarrheal illnesses.

Q: Can I take Nizonide - O with food?

Official product information recommends that Nizonide - O should be taken with food. Taking the medication with a meal is recommended because it may help the body absorb the medicine more effectively, according to product information.

Q: What should I do if I miss a dose of Nizonide - O?

Official prescribing information provides specific guidance on what steps to follow if a dose is missed, including when to take a dose and when to skip it. Patients should review the directions provided by their prescriber or the official product label for detailed instructions.

Q: How quickly does Nizonide - O start working?

Clinical studies suggest that a reduction in symptoms, such as diarrhea, may begin to be observed within 1 to 2 days of starting Nizonide - O treatment. Completing the full course of therapy, as prescribed, is recommended to maximize the chances of fully clearing the parasitic infection.

Q: Can Nizonide - O change the color of my urine?

Yes, official safety information indicates that a temporary effect of Nizonide - O is that it can cause urine to become a yellow-green color. While this color change is expected due to the medicine's metabolites, patients should still discuss any changes or concerns about side effects with a healthcare professional.

Q: Is it possible to take too much Nizonide - O (overdose)?

Regulatory documents mention that information regarding the effects of an overdose of Nizonide - O is limited. If a person suspects they have taken more than the prescribed amount, official information advises patients to seek emergency medical attention.

How should Nizonide - O be stored and disposed of?

Storage and Disposal of Nizonide-O Tablets

All storage and disposal rules for Nizonide-O tablets are established by regulatory authorities to maintain product quality.

Required Storage Conditions

Condition Requirement
Temperature Store at Controlled Room Temperature (25 C or 77 F), with permitted excursions up to 30 C (86 F).
Protection Keep the product in the original container and ensure it is tightly closed.
Environment Must be protected from excess heat and excess moisture.
Child Safety Store strictly out of the reach of children.

Disposal

Unused or expired Nizonide-O must not be kept. Disposal must align with all applicable local and national environmental regulations. If a drug take-back program is unavailable, follow agency-recommended procedures for securing and disposing of the medicine in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Nizonide - O found in:

A-Z Index: